Idiopathic Pulmonary Fibrosis (IPF): Update Bulletin [March 2016]
Gain new KOL insights on the latest events happening in idiopathic pulmonary fibrosis (IPF): Topics covered include opinions about Gilead’s suspension of a Phase II trial of simtuzumab; Boehringer Ingelheim’s initiation of a Phase IV trial combining Esbriet (pirfenidone) with Ofev (nintedanib), as well as views on DS Biopharma’s completion of a Phase I trial of an oral formulation of DS102 (15-HEPE).
- How do KOLs view the recent failure of Gilead’s Phase II trial of simtuzumab?
- Is simtuzumab’s mechanism of action worthy of further investigation for the treatment of IPF?
- How do KOLs rate the importance of Boehringer Ingelheim’s Phase IV trial combining Esbriet with Ofev for the treatment of IPF?
- How do KOLs view combining Esbriet with Ofev in terms of gastrointestinal tolerability and pharmacokinetics?
- Will benefits in terms of efficacy and quality of life justify the high cost of combining Esbriet with Ofev?
- How likely is it that the combination of Esbriet with Ofev will be used in preference to sequential therapy?
- In light of recent data, what is the likelihood that an anti-inflammatory molecule, such as DS Biopharma’s DS102, will constitute a successful treatment approach for IPF?
